Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Поверхностные пиодермии. Современное состояние проблемы
Дворянкова Е.В. Поверхностные пиодермии. Современное состояние проблемы. Дерматология (Прил. к журн. Consilium Medicum). 2019; 3: 19–21. DOI: 10.26442/24143537.2019.3.190600
________________________________________________
Dvoryankova E.V. Superficial pyoderma. Current state of the problem. Dermatology (Suppl. Consilium Medicum). 2019; 3: 19–21. DOI: 10.26442/24143537.2019.3.190600
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Бактериальные инфекционные заболевания кожи широко распространены в популяции и отличаются клиническим разнообразием. Антибиотики – препараты выбора для лечения поверхностных пиодермий. При этом антибиотикорезистентность является важной проблемой современной медицины, что существенно затрудняет терапию пиодермий. Наибольшую распространенность в популяции среди поверхностных пиодермий имеет импетиго. Импетиго – поверхностное инфекционное заболевание кожи, вызываемое золотистым стафилококком либо b-гемолитическими стрептококками группы А, которое широко распространено среди населения разных возрастных групп, но особенно – среди детей. Топические антибиотики являются препаратами выбора для лечения импетиго. По своей эффективности и безопасности они превосходят системные антибактериальные лекарственные средства. Супироцин мазь, основным действующим веществом которой является мупироцин, является топическим антибиотиком для лечения бактериальных инфекций кожи, в том числе импетиго.
Ключевые слова: импетиго, мупироцин, супироцин, антибиотики.
Ключевые слова: импетиго, мупироцин, супироцин, антибиотики.
________________________________________________
Bacterial skin infections are highly prevalent in the population and are highly diverse in clinical manifestation. Antibiotics are first-line therapy for superficial pyoderma. However, antibiotic resistance is a relevant problem of current medicine, which significantly complicates the treatment of pyoderma. Impetigo is the most prevalent in among superficial pyoderma in the population. Impetigo is a superficial infectious skin disease caused by Staphylococcus aureus or group A beta hemolytic streptococci, which highly prevalent in people of different age groups, but especially in children. Topical antibiotics are drugs of choice for the treatment of impetigo. They are superior to systemic antibacterial drugs in their effectiveness and safety. Supirocin ointment, the main active ingredient of which is mupirocin, is a topical antibiotic for the treatment of skin bacterial infections, including impetigo.
Key words: impetigo, mupirocin, supirocin, antibiotics.
Полный текст
Список литературы
1. Lin MY, Hayden MK, Lyles RD et al. Prevention Epicenters Program, Centers for Disease Control and Prevention. Regional Epidemiology of Methicillin-Resistant Staphylococcus aureus Among Adult Intensive Care Unit Patients Following State-Mandated Active Surveillance. Clin Infect Dis 2018; 66 (10): 1535–9.
2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5 (11): 685–94.
3. Bowen AC, Mahe A, Hay RJ et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS ONE 2015; 10: e0136789.
4. Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician 2014; 90 (4): 229–35.
5. Lewis LS, Steele RW. Impetigo. Medscape 2015. www.emedicine.medscape.com/article/965254-overview
6. Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol 2012; 29 (3): 243–8.
7. Soutou B, Aractingi S. Skin disease in pregnancy. Best Pract Res Clin Obstet Gynaecol 2015; 29 (5): 732–40.
8. Roth MM. Pregnancy dermatoses: diagnosis, management, and controversies. Am J Clin Dermatol 2011; 12 (1): 26–39.
9. Sutherland R. Pseudomonic acid, an antibiotic produced by pseudomonas fluorescens. Proceedings of the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1976.
10. Booth JH, Benrimoj SI. Mupirocin in the treatment of impetigo. Int J Dermatol 1992; 31 (1): 1–9.
11. Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. Int J Dermatol 2003; 42 (4): 251–5.
12. Eichenfield LF, Carney PS, Chow MJ et al. Unique approaches for the topical treatment and prevention of cutaneous infections: report from a clinical roundtable. Cutis 2004; 74 (Suppl. 2): 2–23.
13. Koning S, Verhagen AP, van Suijlekom-Smit LW et al. Interventions for impetigo. Cochrane Database Syst Rev 2004; 2: CD003261.
2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5 (11): 685–94.
3. Bowen AC, Mahe A, Hay RJ et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS ONE 2015; 10: e0136789.
4. Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician 2014; 90 (4): 229–35.
5. Lewis LS, Steele RW. Impetigo. Medscape 2015. www.emedicine.medscape.com/article/965254-overview
6. Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol 2012; 29 (3): 243–8.
7. Soutou B, Aractingi S. Skin disease in pregnancy. Best Pract Res Clin Obstet Gynaecol 2015; 29 (5): 732–40.
8. Roth MM. Pregnancy dermatoses: diagnosis, management, and controversies. Am J Clin Dermatol 2011; 12 (1): 26–39.
9. Sutherland R. Pseudomonic acid, an antibiotic produced by pseudomonas fluorescens. Proceedings of the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1976.
10. Booth JH, Benrimoj SI. Mupirocin in the treatment of impetigo. Int J Dermatol 1992; 31 (1): 1–9.
11. Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. Int J Dermatol 2003; 42 (4): 251–5.
12. Eichenfield LF, Carney PS, Chow MJ et al. Unique approaches for the topical treatment and prevention of cutaneous infections: report from a clinical roundtable. Cutis 2004; 74 (Suppl. 2): 2–23.
13. Koning S, Verhagen AP, van Suijlekom-Smit LW et al. Interventions for impetigo. Cochrane Database Syst Rev 2004; 2: CD003261.
________________________________________________
1. Lin MY, Hayden MK, Lyles RD et al. Prevention Epicenters Program, Centers for Disease Control and Prevention. Regional Epidemiology of Methicillin-Resistant Staphylococcus aureus Among Adult Intensive Care Unit Patients Following State-Mandated Active Surveillance. Clin Infect Dis 2018; 66 (10): 1535–9.
2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5 (11): 685–94.
3. Bowen AC, Mahe A, Hay RJ et al. The global epidemiology of impetigo: a systematic review of the population prevalence of impetigo and pyoderma. PLoS ONE 2015; 10: e0136789.
4. Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician 2014; 90 (4): 229–35.
5. Lewis LS, Steele RW. Impetigo. Medscape 2015. www.emedicine.medscape.com/article/965254-overview
6. Bangert S, Levy M, Hebert AA. Bacterial resistance and impetigo treatment trends: a review. Pediatr Dermatol 2012; 29 (3): 243–8.
7. Soutou B, Aractingi S. Skin disease in pregnancy. Best Pract Res Clin Obstet Gynaecol 2015; 29 (5): 732–40.
8. Roth MM. Pregnancy dermatoses: diagnosis, management, and controversies. Am J Clin Dermatol 2011; 12 (1): 26–39.
9. Sutherland R. Pseudomonic acid, an antibiotic produced by pseudomonas fluorescens. Proceedings of the 16th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1976.
10. Booth JH, Benrimoj SI. Mupirocin in the treatment of impetigo. Int J Dermatol 1992; 31 (1): 1–9.
11. Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. Int J Dermatol 2003; 42 (4): 251–5.
12. Eichenfield LF, Carney PS, Chow MJ et al. Unique approaches for the topical treatment and prevention of cutaneous infections: report from a clinical roundtable. Cutis 2004; 74 (Suppl. 2): 2–23.
13. Koning S, Verhagen AP, van Suijlekom-Smit LW et al. Interventions for impetigo. Cochrane Database Syst Rev 2004; 2: CD003261.
Авторы
Е.В. Дворянкова*
ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, Москва, Россия
*dvoriankova@mail.ru
ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН, Москва, Россия
*dvoriankova@mail.ru
________________________________________________
E.V. Dvoryankova*
Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia
*dvoriankova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.